Aglaia BioMedical Ventures

Brisbane, Australia
Firm Location:Brisbane, Australia • Netherlands
Investor Firms That Co-Invest with Aglaia BioMedical Ventures
ForbionBGV (BioGeneration Ventures)
Aglaia BioMedical Ventures Team
Photo of Laurens van der Flier, Analyst at Aglaia BioMedical Ventures
Laurens van der Flier
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Netherlands
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in FinTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in FinTech (Series A)
to see your intro paths to Laurens van
Photo of Mark Krul, Partner at Aglaia BioMedical Ventures
Mark Krul
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Netherlands
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in FinTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in FinTech (Series A)
to see your intro paths to Mark
Photo of Marlies Laros, Analyst at Aglaia BioMedical Ventures
Marlies Laros
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Netherlands
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in FinTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in FinTech (Series A)
to see your intro paths to Marlies
Photo of Karl Rothweiler, Partner at Aglaia BioMedical Ventures
Karl Rothweiler
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Netherlands
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in FinTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in FinTech (Series A)
to see your intro paths to Karl
Photo of Sanne Weijzen, Partner at Aglaia BioMedical Ventures
Sanne Weijzen
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Netherlands
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in FinTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in FinTech (Series A)
to see your intro paths to Sanne